In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre® microdilution method;Actividad in vitro de anfotericina B, itraconazol y voriconazol frente a 20 especies de Aspergillus empleando el método de microdilución Sensititre®

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 1, 2005, Pages 15-18

  García Martos, Pedro ^a,c   García Agudo, Lidia ^a   Gutiérrez Calzada, Jesús ^b   Ruiz Aragón, Jesús ^a   Saldarreaga, Abel ^a   Marín, Pilar ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^b HOSPITAL DE LEÓN   (Spain)

^c NONE   (Spain)

Author keywords

Amphotericin B; Antifungal agents; Aspergillus; Itraconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; ASPERGILLUS CANDIDUS; ASPERGILLUS CHEVALIERI; ASPERGILLUS CLAVATUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS GLAUCUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS OCHRACEUS; ASPERGILLUS ORYZAE; ASPERGILLUS PSEUDOFISCHERI; ASPERGILLUS REPTANS; ASPERGILLUS RUBROBRUNNEUS; ASPERGILLUS SCLEROTIORUM; ASPERGILLUS SYDOWII; ASPERGILLUS TAMARII; ASPERGILLUS TERREUS; ASPERGILLUS UNGUIS; ASPERGILLUS USTUS; ASPERGILLUS VERSICOLOR; DILUTION; FUNGAL STRAIN; MICRODILUTION METHOD; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 14644435065     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070403     Document Type: Article

References (28)

1. Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. Diagn Microbiol Infect Dis 2001;41:211-4.
2. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus with a head-to-head comparison to voriconazole. J Clin Microbiol 1999;37:2343-5.
3. Measaki S, Iwakawa J, Higashiyama Y, et al. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp. J Infect Chemother 2000;6:101-3.
4. Meletieadis J, Mouton JW, Meis JF, Bouman BA, Verweij PE. Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2002;40:2876-85.
5. Martín-Mazuelos E, Pemán J, Valverde A, Chaves M, Serrano MC, Cantón E. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003;52:365-70.
6. Sánchez-Sousa A, Álvarez ME, Maíz L, Escobar H, Baquero F. Aspergillus fumigatus susceptibility testing by colorimetric microdilution. J Mycol Med 1999;9:103-6.
7. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi. Approved Standard M38-A NCCLS, Wayne, PA, USA, 2002.
8. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand J Infect Dis 1997;29:509-12.
9. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1364-8.
10. Denning DW, Radford SA, Oakley KL, Hall L, Johson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997;40:401-14.
11. Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998;42:282-8.
12. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998;17:573-5.
13. Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998;42:741-5.
14. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvina. Mycoses 1998;41:309-19.
15. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57-62.
16. Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44:441-3.
17. Dannaoui E, Persat F, Monier MF, Borel MAP, Picot S. In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother 1999;44:553-5.
18. Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW. In vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998;42:389-92.
19. Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis 1999;33:7-11.
20. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41:696-8.
21. Rath PM. Susceptibility of Aspergillus strains from culture collections to amphotericin B and itraconazole. J Antimicrob Chemother 1998;41: 567-70.
22. Torres-Rodríguez JM, Madrenys-Brunet N, Siddat M, López-Jodra O, Jiménez T. Aspergillus versicolor as cause of onychomycosis: report of 12 cases and susceptibility testing to antifungal drugs. J Eur Acad Dermatol Venereol 1998;11:25-31.
23. Verweij PE, Oakley KL, Morrissey J, Morrisey G, Denning DW. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998;42:873-8.
24. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 2000;49:601-6.
25. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002;40:2648-50.
26. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001;47:333-40.
27. Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, Martínez-Suárez JV, Monzón A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998;42:531-3.
28. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002;46:556-7.